Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.61 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17398765 | 0.94 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL19097481 | 0.93 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1ALDH1A1MEN1GAA | |
| SCHEMBL17398161 | 0.93 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL17398201 | 0.92 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL17398175 | 0.91 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL17398194 | 0.91 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL17398169 | 0.91 | GUCY1A1 (0.56) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL17398243 | 0.90 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1 | |
| SCHEMBL19097470 | 0.89 | GUCY1A1 (0.65) | GUCY1A1GUCY1B1 | |
| SCHEMBL17398338 | 0.89 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3164399-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001876-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B2, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 4/4885KDM4E 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.